SCHEMBL6902830

SCHEMBL6902830

CC(=O)Oc1ccc(N(C=O)CC(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
ELANE P08246 1/20 0.45
HSD17B10 Q99714 2/20 0.44
MAPT P10636 3/20 0.42
GAA P10253 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HSP90AA1 P07900 1/20 0.42
POLB P06746 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
KDM4E B2RXH2 2/20 0.41
TTR P02766 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6907195 0.84 KMT2A (0.45) LMNAELANEHSD17B10MAPTGAA
SCHEMBL6906705 0.83 LMNA (0.46) LMNAELANEHSD17B10MAPTALDH1A1
SCHEMBL6906627 0.82 LMNA (0.47) LMNAMAPTGAAKMT2AMEN1
SCHEMBL6905904 0.81 LMNA (0.40) LMNAELANEHSD17B10MAPTGAA
SCHEMBL22468229 0.79 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2KEAP1NFE2L2
SCHEMBL6902198 0.79 LMNA (0.47) LMNAELANEHSD17B10MAPTGAA
SCHEMBL22468266 0.79 SMN1; SMN2 (0.57) ALDH1A1HSP90AA1POLBSMN1; SMN2NPC1
SCHEMBL6906580 0.78 LMNA (0.43) LMNAELANEHSD17B10MAPTGAA
SCHEMBL6738381 0.76 KEAP1 (0.46) GAAPOLBKMT2AKEAP1NFE2L2
SCHEMBL26117099 0.76 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 LMNA 1347/4885ELANE 1958/4885HSD17B10 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.